Trial Profile
A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2020
Price :
$35
*
At a glance
- Drugs CBLC 137 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cleveland BioLabs; Incuron
- 08 Dec 2020 Status changed from suspended to discontinued.
- 20 May 2020 Planned number of patients changed from 110 to 230.
- 20 May 2020 Planned End Date changed from 1 Nov 2019 to 1 Dec 2020.